{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:30:12Z","timestamp":1740130212087,"version":"3.37.3"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"internal funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,12]]},"DOI":"10.1093\/jac\/dkab192","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T11:07:37Z","timestamp":1621681657000},"page":"2484-2485","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and tolerability of combined antiretroviral treatment with bictegravir\/emtricitabine\/tenofovir alafenamide initiated at the time of primary HIV infection"],"prefix":"10.1093","volume":"76","author":[{"given":"A","family":"Bachelard","sequence":"first","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Isernia","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Vallois","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Le Gac","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Chalal","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Landman","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"},{"name":"IAME\u2014UMR 1137 INSERM, Universit\u00e9 de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Damond","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME\u2014UMR 1137 INSERM, Universit\u00e9 de Paris, Paris, France"},{"name":"AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"},{"name":"IAME\u2014UMR 1137 INSERM, Universit\u00e9 de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"G","family":"Peytavin","sequence":"additional","affiliation":[{"name":"IAME\u2014UMR 1137 INSERM, Universit\u00e9 de Paris, Paris, France"},{"name":"AP-HP, Hospital Bichat-Claude Bernard, Pharmacology-Toxicology Laboratory, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ghosn","sequence":"additional","affiliation":[{"name":"AP-HP, Hospital Bichat\u2014Claude-Bernard, Infectious and Tropical Diseases, Paris, France"},{"name":"IAME\u2014UMR 1137 INSERM, Universit\u00e9 de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"2021081309090187000_dkab192-B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"2021081309090187000_dkab192-B2"},{"key":"2021081309090187000_dkab192-B3","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled noninferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2021081309090187000_dkab192-B4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2021081309090187000_dkab192-B5"},{"key":"2021081309090187000_dkab192-B6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkq035","article-title":"Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort","volume":"65","author":"Ghosn","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021081309090187000_dkab192-B7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled noninferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2021081309090187000_dkab192-B8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"author":"Ruderman","key":"2021081309090187000_dkab192-B9"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2484\/39711729\/dkab192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2484\/39711729\/dkab192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T09:14:38Z","timestamp":1628846078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/9\/2484\/6295675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,10]]},"published-print":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab192","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,10]]}}}